Abstract:BackgroundNeoadjuvant chemotherapy is recommended for BRPC and LAPC planned resection. PD-1 antibody alone failed in advanced pancreatic cancer previously, but chemotherapy combined with PD-1 antibody are promising. The aim of this study is to investigate whether neoadjuvant chemotherapy plus PD-1 antibody can result in better outcomes.MethodsThis is a randomized, controlled, open-label phase II study including patients with BRPC or LAPC. Modified FOLFIRINOX (mFFX) is used as neoadjuvant chemotherapy. Patients will be randomly allocated into two groups: mFFX group and mFFX plus PD-1 antibody group (PD-1 group). Imaging evaluation will be discussed by the MDT. Surgical resection will be performed if the MDT confirms the resectability. (NCT03983057).ResultsFrom March 4th 2019 to August 1st 2021, 146 patients were enrolled and randomized. Of the 146 patients, 62 (42.4%) were BRPC and 84 (57.5%) were LAPC. Among them, 115 patients received at least four cycles of mFFX or mFFX plus PD-1 antibody and completed radiological evaluation at least once. Grade 3 neutropenia was common in both groups. And in mFFX plus PD-1 antibody group, immune-related adverse events (irAEs) happened in seven patients (9.7%), including rash (3 patients, all were Grade 1), hepatic AE (2 patients Grade 3, 1 patient Grade 2), renal AE (2 patients, both Grade 2), and hyperglycemia with diabetic ketoacidosis (2 patients). All of the seven patients were relieved after proper treatment. Radiological partial response was noted in 13.3% patients in mFFX group, and 26.9% in mFFX plus PD-1 antibody group. Notably, for BRPC patients, the radiological partial response was 13.0% and 36.3% in two groups, respectively. The resection rate was similar in the two groups (47.4% and 51.7%). R0 resections were performed in 70.3% and 86.6% patients, respectively. However, for LAPC patients, mFFX plus PD-1 antibody group was noted in a higher resection rate (37.1% vs. 48.0%). The survival data are not mature at present.ConclusionsModified FOLFIRINOX plus PD-1 antibody is feasible and well-tolerated for BRPC and LAPC patients. The study will be continued and the detailed data will be reported.Clinical trial identificationNCT03983057.Legal entity responsible for the studyThe authors.FundingKey clinical study foundation of the First Affiliated Hospital, Zhejiang University School of Medicine.DisclosureAll authors have declared no conflicts of interest. BackgroundNeoadjuvant chemotherapy is recommended for BRPC and LAPC planned resection. PD-1 antibody alone failed in advanced pancreatic cancer previously, but chemotherapy combined with PD-1 antibody are promising. The aim of this study is to investigate whether neoadjuvant chemotherapy plus PD-1 antibody can result in better outcomes. Neoadjuvant chemotherapy is recommended for BRPC and LAPC planned resection. PD-1 antibody alone failed in advanced pancreatic cancer previously, but chemotherapy combined with PD-1 antibody are promising. The aim of this study is to investigate whether neoadjuvant chemotherapy plus PD-1 antibody can result in better outcomes. MethodsThis is a randomized, controlled, open-label phase II study including patients with BRPC or LAPC. Modified FOLFIRINOX (mFFX) is used as neoadjuvant chemotherapy. Patients will be randomly allocated into two groups: mFFX group and mFFX plus PD-1 antibody group (PD-1 group). Imaging evaluation will be discussed by the MDT. Surgical resection will be performed if the MDT confirms the resectability. (NCT03983057). This is a randomized, controlled, open-label phase II study including patients with BRPC or LAPC. Modified FOLFIRINOX (mFFX) is used as neoadjuvant chemotherapy. Patients will be randomly allocated into two groups: mFFX group and mFFX plus PD-1 antibody group (PD-1 group). Imaging evaluation will be discussed by the MDT. Surgical resection will be performed if the MDT confirms the resectability. (NCT03983057). ResultsFrom March 4th 2019 to August 1st 2021, 146 patients were enrolled and randomized. Of the 146 patients, 62 (42.4%) were BRPC and 84 (57.5%) were LAPC. Among them, 115 patients received at least four cycles of mFFX or mFFX plus PD-1 antibody and completed radiological evaluation at least once. Grade 3 neutropenia was common in both groups. And in mFFX plus PD-1 antibody group, immune-related adverse events (irAEs) happened in seven patients (9.7%), including rash (3 patients, all were Grade 1), hepatic AE (2 patients Grade 3, 1 patient Grade 2), renal AE (2 patients, both Grade 2), and hyperglycemia with diabetic ketoacidosis (2 patients). All of the seven patients were relieved after proper treatment. Radiological partial response was noted in 13.3% patients in mFFX group, and 26.9% in mFFX plus PD-1 antibody group. Notably, for BRPC patients, the radiological partial response was 13.0% and 36.3% in two groups, respectively. The resection rate was similar in the two groups (47.4% and 51.7%). R0 resections were performed in 70.3% and 86.6% patients, respectively. However, for LAPC patients, mFFX plus PD-1 antibody group was noted in a higher resection rate (37.1% vs. 48.0%). The survival data are not mature at present. From March 4th 2019 to August 1st 2021, 146 patients were enrolled and randomized. Of the 146 patients, 62 (42.4%) were BRPC and 84 (57.5%) were LAPC. Among them, 115 patients received at least four cycles of mFFX or mFFX plus PD-1 antibody and completed radiological evaluation at least once. Grade 3 neutropenia was common in both groups. And in mFFX plus PD-1 antibody group, immune-related adverse events (irAEs) happened in seven patients (9.7%), including rash (3 patients, all were Grade 1), hepatic AE (2 patients Grade 3, 1 patient Grade 2), renal AE (2 patients, both Grade 2), and hyperglycemia with diabetic ketoacidosis (2 patients). All of the seven patients were relieved after proper treatment. Radiological partial response was noted in 13.3% patients in mFFX group, and 26.9% in mFFX plus PD-1 antibody group. Notably, for BRPC patients, the radiological partial response was 13.0% and 36.3% in two groups, respectively. The resection rate was similar in the two groups (47.4% and 51.7%). R0 resections were performed in 70.3% and 86.6% patients, respectively. However, for LAPC patients, mFFX plus PD-1 antibody group was noted in a higher resection rate (37.1% vs. 48.0%). The survival data are not mature at present. ConclusionsModified FOLFIRINOX plus PD-1 antibody is feasible and well-tolerated for BRPC and LAPC patients. The study will be continued and the detailed data will be reported. Modified FOLFIRINOX plus PD-1 antibody is feasible and well-tolerated for BRPC and LAPC patients. The study will be continued and the detailed data will be reported.

PRIMUS-002: A multicentre, open-label, phase II study examining FOLFOX and nab-paclitaxel (FA) and nab-paclitaxel and gemcitabine (AG) as neoadjuvant therapy for (borderline) resectable pancreatic cancer (PC), focusing on biomarker and liquid biopsy development.

Phase 2 study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node-positive pancreatic ductal adenocarcinoma

Efficacy and safety of neoadjuvant therapy with stereotactic body radiation therapy followed by nab-paclitaxel/gemcitabine plus camrelizumab for resectable, borderline resectable and locally advanced pancreatic cancer: Preliminary results.

Abstract A002: A phase II study of peri-operative modified FOLFIRINOX in localized pancreatic ductal adenocarcinoma (PDAC)

PD-1 Blockade Plus Chemotherapy Followed by Concurrent SBRT with SIB As Preoperative Therapy for Patients with Borderline Resectable and Locally Advanced Pancreatic Cancer: A Biomolecular Exploratory, Single-Arm Phase II Clinical Trial

Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysis

146P Randomized Phase II Trial of Neoadjuvant Chemotherapy with Modified FOLFIRINOX Versus Modified FOLFIRINOX and PD-1 Antibody for Borderline Resectable and Locally Advanced Pancreatic Cancer (the CISPD-4 Study)

Abstract A001: Preoperative treatment with mFOLFIRINOX +/- isotoxic high-dose stereotactic body radiation therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial): A randomized comparative multicenter phase II trial

Sintilimab Plus Oxaliplatin/capecitabine (capeox) As Neoadjuvant Therapy in Patients with Locally Advanced, Resectable Gastric (g)/esophagogastric Junction (GEJ) Adenocarcinoma.

Abstract CT031: A pilot clinical trial of neoadjuvant modified FOLFIRINOX plus nivolumab in borderline resectable pancreas cancer

Phase I study of PTM-101 as neoadjuvant therapy for borderline resectable or locally advanced pancreatic ductal adenocarcinoma: A trial in progress.

Induction Chemotherapy With FOLFIRINOX Followed by Chemoradiation With Gemcitabine in Patients With Borderline-Resectable Pancreatic Ductal Adenocarcinoma

Paclitaxel protein bound (A) plus gemcitabine (G) plus cisplatin (C) and hydroxychloroquine (HCQ) neoadjuvant therapy for localized pancreatic ductal adenocarcinoma (PDAC).

Early results of the PASS-01 trial: Pancreatic adenocarcinoma signature stratification for treatment-01.

AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer

A phase I/II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced (LA) and borderline resectable (BR) pancreatic cancer.

Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclitaxel, gemcitabine, and concurrent radiotherapy as the induction therapy for patients with locally advanced and borderline resectable pancreatic cancer

Efficacy and safety of neoadjuvant nab-paclitaxel plus gemcitabine therapy in patients with borderline resectable pancreatic cancer: A multicenter single-arm phase II study (NAC-GA trial)

Neoadjuvant‐modified FOLFIRINOX vs nab‐paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection

Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy (RT) for borderline resectable (BR) adenocarcinoma of the pancreas.